ライフサイエンスコーパス: VLDL receptor

1 he C-terminus, which mediates binding to the VLDL receptor.

2 FPI is mediated through interaction with the VLDL receptor.

3 ity is mediated through interaction with the VLDL receptor.

4 receptor, LDL receptor-related protein, and VLDL receptor.

5 ss endothelial cells involves both HSPGs and VLDL receptor.

6 hat RAP is associated with newly synthesized VLDL receptor.

7 urther studied using an anchor-free, soluble VLDL receptor.

8 amino-terminal ligand-binding repeats of the VLDL receptor.

9 he first three ligand-binding repeats of the VLDL receptor.

10 RAP, an antagonist of ligand binding to the VLDL receptor.

11 this property was reversed by expressing the VLDL receptor, a member of the same gene family as LRP-1

12 ependent augmentation of LTP is abolished in VLDL receptor and apoER2 knockout mice.

13 ferative activity of TFPI is mediated by the VLDL receptor and suggest that this receptor-ligand syst

14 receptors, the very low density lipoprotein (VLDL) receptor and apoE receptor 2 (apoER2), are also re

15 330/LRP-2, and very low density lipoprotein (VLDL) receptors and induces receptor-mediated lipoprotei

16 a known antagonist of ligand binding by the VLDL receptor, and by anti-VLDL receptor antibodies.

17 tion was prevented by antibodies against the VLDL receptor, and by RAP, an antagonist of ligand bindi

18 perone for the very low density lipoprotein (VLDL) receptor, another member of the LDL receptor gene

19 cells was treated with antibodies, only anti-VLDL receptor antibodies inhibited transcytosis.

20 nd binding by the VLDL receptor, and by anti-VLDL receptor antibodies.

21 AH secretion, but also identify the maternal VLDL receptor as a key genetic program that ensures milk

22 ay involve the very low density lipoprotein (VLDL) receptor because the in vitro antiproliferative ac

23 Our data demonstrate that this VLDL receptor-binding fragment of the TFPI molecule has

24 ecently cloned very low density lipoprotein (VLDL) receptor binds triglyceride-rich, apolipoprotein-E

25 strate that fibroblasts expressing the human VLDL receptor can mediate endocytosis of Lp(a), leading

26 Using truncated VLDL receptor constructs, we identified the RAP-binding

27 VLDL receptor-deficient mice also have a moderate defect

28 VLDL receptor deletion significantly impairs the express

29 that maternal very-low-density-lipoprotein (VLDL) receptor deletion in mice causes the production of

30 ence of RAP co-expression, newly synthesized VLDL receptor exhibited slower trafficking along the ear

31 The functions of RAP in VLDL receptor folding and trafficking were mediated by i

32 An important role for the VLDL receptor for contributing to differences in VLDL bi

33 n of recombinant adenoviruses containing the VLDL receptor gene corrected the dsylipidaemia in the FH

34 cytoplasmic domain of apoER2 in the LDL- or VLDL-receptor genes was investigated, but nucleotide seq

35 g a helper-dependent adenovirus encoding the VLDL receptor (HD-Ad-VLDLR) under control of a liver-sel

36 We also demonstrate the expression of the VLDL receptor in macrophages present in human atheroscle

37 ese findings not only reveal a novel role of VLDL receptor in suppressing inflammation by maintaining

38 As expression of the VLDL receptor in the vascular wall might have important

39 The widespread distribution of the VLDL receptor in vascular tissue suggests a potentially

40 y the very low density lipoprotein receptor (VLDL receptor) indicating that this receptor is a novel

41 pared with control mice, indicating that the VLDL receptor may play an important role in Lp(a) catabo

42 nd immunohistochemistry to determine whether VLDL receptor mRNA and protein was expressed in human va

43 The observation that VLDL receptor mRNA is abundantly expressed in extracts o

44 Mice lacking either the VLDL receptor or the apoER2 show contextual fear conditi

45 rotein and the very low density lipoprotein (VLDL) receptor, or specific receptor antibodies.

46 The ability of the VLDL receptor to mediate endocytosis of Lp(a) could lead

47 Moreover, overexpression of the VLDL receptor using adenoviral-mediated gene transfer in

48 a folding and trafficking chaperone for the VLDL receptor via interactions of its carboxyl-terminal

49 for Reelin or Dab1, or doubly mutant for the VLDL receptor (VLDLR) and ApoE receptor 2 (ApoER2), show

50 We delivered the VLDL receptor (VLDLR) to the liver of LDLR-deficient mic

51 scle LPL activity and mRNA levels of LPL and VLDL receptor (VLDLr) were also increased in Ad-mACRP30-

52 increased the levels of the Reelin receptor (VLDL receptor (VLDLR)) in hippocampal neurons by increas

53 LDL receptor-related protein 1 (LRP1) to the VLDL receptor (VLDLR), which internalized apoE4 and Abet

54 The experiments showed that very LDL (VLDL) receptor (VLDLR) interacts with high affinity with

55 Although very low density lipoprotein (VLDL) receptor (VLDLr) knockout mice have been reported

56 In the latter, the VLDL receptor was also expressed by macrophage-derived f

57 nts showed that while only 3% of the soluble VLDL receptor was folded and secreted in the absence of

58 The role of RAP in the folding of the VLDL receptor was further studied using an anchor-free,

59 ligand for the very-low-density lipoprotein (VLDL) receptor, we hypothesized that TFPI overexpression

60 ulation was delayed in mice deficient in the VLDL receptor when compared with control mice, indicatin

61 e liver of the very low density lipoprotein (VLDL) receptor, which is homologous to the LDL receptor